Eenzyme Mouse Igm Antibody To Rbd-Spike

Anti-Spike-RBD-human-mAb(IgM)

E24AHA005 Humanized-Monoclonal-Antibody.human-IgM
EUR 416.5
Description: Humanized Monoclonal Antibody.human IgM

Igm Antibody Laboratories manufactures the eenzyme mouse igm antibody to rbd-spike reagents distributed by Genprice. The Eenzyme Mouse Igm Antibody To Rbd-Spike reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact igm antibody. Other Eenzyme products are available in stock. Specificity: Eenzyme Category: Mouse Group: Igm Antibody

Anti-Spike-RBD mAb

10mg Ask for price
Description: Anti-Spike-RBD mAb

Anti-Spike-RBD mAb

1g Ask for price
Description: Anti-Spike-RBD mAb

Anti-Spike-RBD mAb

1mg Ask for price
Description: Anti-Spike-RBD mAb

Anti-Spike-RBD mAb

50mg Ask for price
Description: Anti-Spike-RBD mAb

Anti-Spike-RBD mAb

5mg Ask for price
Description: Anti-Spike-RBD mAb

SARS-CoV-2-Spike-RBD-Polyclonal-Antibody

2019-nCoV-rabbit-polyclonal-antibody
EUR 276.5
Description: 2019-nCoV rabbit polyclonal antibody

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122)

100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

Igm Antibody information

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1 each Ask for price

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-100 100
EUR 148.12
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-1000 1000
EUR 880.6
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-2000 2000
EUR 1565.2
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-250 250
EUR 246.17
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-50 50
EUR 89.54
Description: Primary VHH single domain antibody

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS113) (Omicron Specific)

SPD-M305 100ug
EUR 5927.8
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus and other viral lineages.

SARS-CoV-2 Spike Glycoprotein RBD Antibody Pair

abx243136-96tests 96 tests
EUR 950

Human Anti-SARS CoV 2 Spike RBD Antibody(hFC)

E2S209906 100ul
EUR 595
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS106) (Beta & Gamma Specific)

SPD-M416 100ug
EUR 5703.1
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Beta (B.1.351) and Gamma (P.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus, the Alpha (B.1.1.7) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529, BA.2) variant.

Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing)

MERS125-M 100 ul
EUR 578.4

Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 (2G7F5) (MALS verified)

SPD-Y68 100ug
EUR 2493.1
Description: Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike protein.

SARS-CoV-2 Spike RBD protein antibody pair 1

CSB-EAP33245 1 pair
EUR 900
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA.

SARS CoV-2 IgM Spike S1 (CoV-2 IgM S1) Antibody

abx137721-100tests 100 tests
EUR 225

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).